. Boehringer Ingelheim’s PRRS vaccine celebrates 25 years of presence in Europe
•The Company has been offering a holistic approach to veterinarians and producers to control PRRS through collaborative research, innovative diagnostics and services.
Ingelheim, Germany, June 30, 2021 – Boehringer Ingelheim, a global leader in animal health, is proud to celebrate 25 years of partnering with veterinarians and producers to combat PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe and more than 25 years in the US. In addition to offering a leading1 full range of PRRS modified-live vaccines including Ingelvac® PRRS MLV, Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU, the Company is in the unique position to offer a holistic approach to PRRS control through collaborative research, innovative diagnostics and services.
Martin Forchieri, Head of Vaccine Franchise, Swine Business at Boehringer Ingelheim, shared: “All too often the term ‘journey’ is used for what merely turns out to be projects – with regards to Ingelvac® PRRS MLV though, it has been and continues to be a learning journey at its best. Over the last 25 years both Boehringer Ingelheim as well as the swine industry have learned so much about how to best control and prevent PRRS. Harvesting such learnings contributes to better PRRS control as well as to more efficient swine health management overall spreading across diseases, disciplines and technologies – what a journey indeed.”
Boehringer Ingelheim PRRS franchise has been the market leader in PRRS vaccine segment for more than 10 years2. The Company achieved more than 1.7 billion doses sold of PRRS Franchise in 2020 since Ingelvac® PRRS MLV was launched in 1994 in the US; the product was approved two years later in Europe. In addition, 2015 saw a launch of Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU against PRRSV type 1 infection in the EU.
As a science-driven company, Boehringer Ingelheim has sponsored the European PRRS Research Award for 16 years to support applied research for improved control of the PRRS swine disease, as well as more than 48 research projects with value of 1.2 million euro to support the innovation of PRRS control.
The Company is proud to have been continuously able to improve pig health and performance, its customers’ production and profit - today and in the future.
Porcine Reproductive and Respiratory Syndrome
Porcine Reproductive and Respiratory Syndrome (PRRS) is a viral disease infecting sows and pigs leading to reproductive failure (abortions, weak and stillborn piglets, infertility), and causes pneumonia and increased mortality in young pigs. From early studies two different genotypes of PRRSv are recognized, designated as genotype 1 (formerly known as European (EU)) and genotype 2 (formerly known as North American). PRRS is considered to be the most economically important viral disease in most of the main pig production countries across the globe. It is a global problem, affecting the swine industry worldwide, the total cost to the industry has been estimated at 4 billion euro per year and 1.5 billion euro annually in EU.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.